{"id":273306,"date":"2026-09-28T10:13:29","date_gmt":"2026-09-28T04:43:29","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=273306"},"modified":"2026-09-28T10:13:29","modified_gmt":"2026-09-28T04:43:29","slug":"sun-pharma-lerodalcibep-deal","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/sun-pharma-lerodalcibep-deal\/","title":{"rendered":"Sun Pharma Buys Its Way Into the $3.7 Billion PCSK9 Market: What the Lerodalcibep Licensing Deal Adds"},"content":{"rendered":"

Sun Pharma lerodalcibep rights outside US and China. EU approved 21 Sep. Market $3.7bn ex-US and China, 38% CAGR. Stock near Rs 1,847, P\/E 36.7 vs industry 38.4.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

The Sun Pharma lerodalcibep deal is an exclusive licence to commercialise and manufacture the once-monthly cholesterol drug worldwide, excluding the United States and China, signed with LIB Therapeutics. The drug is approved in the EU as Lyrokaul and targets a PCSK9 inhibitor market of $3.7 billion outside the US and China that is growing at 38 percent a year. Financial terms are confidential beyond an upfront payment, milestones and royalties to LIB, so the shares reacted little, trading near Rs 1,847.<\/p>\n<\/div>\n

Sun Pharmaceutical Industries<\/a> and LIB Therapeutics announced an exclusive licensing agreement on 28 September for lerodalcibep, a PCSK9 inhibitor that lowers LDL cholesterol. Sun Pharma gets rights to commercialise and manufacture the drug across every market except the United States and China, and it will be responsible for obtaining regulatory approvals in licensed territories where the drug is not yet approved.<\/p>\n

LIB will receive an upfront payment, future milestone payments and royalties on net sales in the licensed territories. Other terms are confidential, which limits how far investors can model the impact, but the deal adds a cardiovascular product to the company’s innovative medicines portfolio at a point when the drug has just cleared its most important approval.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n